Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure

AIMS: Sodium–glucose co‐transporter (SGLT)‐2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular risk in two large clinical outcome trials: empagliflozin in EMPA‐REG OUTCOM...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Abhinav, Wu, Jingjing, Ezekowitz, Justin A., Felker, Gary Michael, Udell, Jacob A., Heidenreich, Paul A., Fonarow, Gregg C., Mahaffey, Kenneth W., Hernandez, Adrian F., DeVore, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083448/
https://www.ncbi.nlm.nih.gov/pubmed/31747132
http://dx.doi.org/10.1002/ehf2.12528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083448/
https://www.ncbi.nlm.nih.gov/pubmed/31747132
http://dx.doi.org/10.1002/ehf2.12528

Ejemplares similares